Results 261 to 270 of about 4,236,805 (394)

Data Sheet 3_Causal link between mental disorders and gastrointestinal diseases: a Mendelian randomization study.pdf

open access: green
Wenjing Ding (1699807)   +6 more
openalex   +1 more source

Conserved interdomain linker promotes phase separation of the multivalent adaptor protein Nck

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2015
Sudeep Banjade   +5 more
semanticscholar   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Conformational Dynamics in the Cell Membrane Interactions of Bispecific Targeted Degrader Therapeutics. [PDF]

open access: yesJ Med Chem
Inganäs E   +7 more
europepmc   +1 more source

S1 Data - Direct and indirect pathways linking the Lon protease to motility behaviors in the pathogen Pseudomonas aeruginosa

open access: green
Aswathy Kallazhi (21602291)   +3 more
openalex   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga   +2 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy